Menlo Park, United States
GRAIL, founded in 2016, is a pioneering Biotechnology company based in the United States with a mission to "Detect cancer early, when it can be cured." The company aims to revolutionize cancer care by focusing on early detection using cutting-edge technologies like next-generation sequencing (NGS) and state-of-the-art computer and data science. With a robust interdisciplinary team, GRAIL is addressing one of medicine’s most daunting challenges — reducing cancer mortality.
Headquartered in Menlo Park, California, with additional locations in Washington, D.C., North Carolina, and the UK, GRAIL has garnered support from prominent global investors, including PSP Investments, Huangpu River Capital, Canada Pension Plan Investment Board, and Illumina. Its latest funding was a hefty $390.00M in a Series D investment on 06 May 2020.
